2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Bacterial, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric
PAPER

4451 Humanistic burden of warm autoimmune hemolytic anemia from the physician and patient’s perspective – results from a real-world survey

Irina Murakhovskaya, MD, Louis Jackson, PharmD2, Jacqueline Pesa, MSEd, PhD, MPH3, Stephen Fortin4, Susanna Libby5, Kieran Wynne-Cattanach, MSc6, Katherine Smethers, MSci7, Emily Quinones8, Surbhi Shah, MBBS, MD9
1 Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States
2 Johnson & Johnson, Horsham, Pennsylvania, United States
3 Johnson & Johnson, Horsham, Pennsylvania, United States
4 Johnson & Johnson, Horsham, Pennsylvania, United States
5 Adelphi Real World, Bollington, United Kingdom
6 Adelphi Real World, Bollington, United Kingdom
7 Adelphi Real World, Bollington, United Kingdom
8 Adelphi Real World, Bollington, United Kingdom
9 Mayo Clinic Hematology & Oncology, Phoenix, Arizona, United States

Background:

Warm autoimmune hemolytic anemia (wAIHA) is a form of autoimmune hemolytic anemia, characterized by immunoglobin G autoantibodies which react to and destroy erythrocytes at 37°C. Current real-world data related to burden of illness is limited. The current study aims to describe the humanistic burden of wAIHA.

Methods:

Data were drawn from the Adelphi wAIHA I Disease Specific Programme™, a cross-sectional survey with elements of retrospective data collection of physicians and their patients with wAIHA conducted in the United States of America (February-October 2025). Physicians completed forms for up to their next 10 consecutively consulting patients with wAIHA capturing patient demographics, manifestations of wAIHA, and the impact of wAIHA on patient and caregiving needs. Identical forms were completed for a subset of patients who had received ≥1 rituximab cycle. Patients voluntarily completed a form, which included the Work Productivity and Activity Impairment (WPAI) questionnaire, the Patient Global Impression of Severity (PGI-S) questionnaire and the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Normative values of general population-based studies report mean (SD) FACIT-Fatigue scores of 43.5 (8.3) (Montan et al.). Correlation analysis was used to assess association between FACIT-Fatigue scores and WPAI domain scores. All other analyses were descriptive.

Results:

Overall, 36 physicians provided data for 361 patients, among which, 76.5% of patients had primary wAIHA, 47.4% of patients were male, and 77.3% were White. The mean (standard deviation [SD]) patient age was 51.0 (15.7) years, body mass index was 26.4 (4.0) kg/m2, and time from diagnosis was 15.7 (16.4) months. Self-report forms were completed by 67 of these patients.

Physicians reported 56.9% of patients with available anemia data (n=360) had none or mild anemia (≥10g/dL hemoglobin) at time of survey, and 43.1% had moderate or severe anemia (<10g/dL hemoglobin). Physicians reported medium to high impact of wAIHA on quality of life in 54.3% of patients with none to mild anemia, and 65.5% of patients with moderate to severe anemia. Medium to high impact of wAIHA was most commonly reported in patients with moderate to severe anemia with respect to physical activities (52.3% for patients with none to mild anemia; 68.9% for patients with moderate to severe anemia), daily life (53.8%; 74.2%), emotional well-being (46.9; 63.2%), work life (50.0%; 61.2%), work and productivity (43.8%; 54.6%), and mental health (51.2%; 52.9%).

Of 63 patients who provided caregiver support data, 25.4% self-reported receiving caregiver support, most commonly their partner/spouse (22.2%). Where physicians knew patient employment (n=355), physicians reported 70.7% were employed and 3.4% were students, with 13.0% and 22.2% of patients had been prescribed sick leave due to wAIHA respectively, with a mean (SD) of 28.0 (19.1) days off in the 12 months prior to survey. Via the WPAI, patients reported mean (SD) percentage overall work productivity loss of 25.3% (25.4%), overall work time missed of 7.0% (21.7%), impairment while working of 23.3% (24.5%) and activity impairment of 28.4% (27.3%).

Mean (SD) patient reported FACIT-Fatigue scores (n=67) were 36.0 (12.4) overall, 38.9 (13.2) in patients with none to mild anemia (n=22), and 34.5 (11.8) in patients with moderate to severe anemia (n=45), with lower FACIT-fatigue scores indicating more severe fatigue. Overall, 55 (82.1%) patients reported experiencing fatigue in the week prior to survey via the PGI-S.

A strong, significant negative correlation was observed between FACIT-Fatigue and WPAI domains of overall work impairment (r=-0.7992, p<0.0001), activity impairment (r=-0.7723, p<0.0001) and impairment while working (r=-0.7347, p<0.0001) due to wAIHA, indicating an association between increased fatigue and increased work impairment. No significant relationship was observed between FACIT-Fatigue and work time missed due to wAIHA (r=0.0164, p=0.9178).

Conclusion:

Our results demonstrate that both wAIHA patients and physicians acknowledge a substantial burden of disease with complementary perspectives. Although burden was greatest among patients with moderate to severe anemia; substantial fatigue, quality of life impairment, and productivity loss persisted among wAIHA patients with hemoglobin ≥10 g/dL. These results demonstrate the importance of effective treatment and management of anemia in wAIHA patients.

Louis Jackson, PharmD: Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment